<DOC>
	<DOCNO>NCT00911495</DOCNO>
	<brief_summary>This Phase 1/Phase 2 study evaluate GMI-1070 , pan-selectin inhibitor , adult stable sickle cell disease . The study ass safety , pharmacokinetics , microvascular effect intravenous GMI-1070 outpatient setting .</brief_summary>
	<brief_title>Study Intravenous GMI-1070 Adults With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Age 18 45 year Established diagnosis SCDSS SCDSB0thal At medical baseline , evidence worsen disease last 3 month Available agree return followup visit full duration study Able cooperate study procedure Documented observe write informed consent Vasoocclusive crisis Recent major surgery , hospitalization , infection , significant bleeding , cerebrovascular accident seizure , transfusion Currently receiving , receive within previous 4 week , investigational agent Pregnant lactate female ; female childbearing age unable unwilling comply birth control abstinence course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Sickle Cell Disease</keyword>
</DOC>